

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Full Name: _____ DOB: _____ Phone: _____ Gender: ☐ M ☐ F ☐ Other

Email Address: _____ Address: _____ Weight (lbs/kg): _____ Height (in): _____

☐ NKDA Allergies: _____ Existing prior authorization? ☐ Yes, (Send a copy) ☐ No (AIC will process)

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

Patient Preferred Location: _____

DIAGNOSIS & CLINICAL INFORMATION

ICD 10-Code & Description (Provide full completed code & description)

Primary Diagnosis must be checked:

☐ Z00.6 Encounter for examination for normal comparison and control in clinical research program

Secondary Diagnosis:

☐ G31.84 Mild Cognitive Impairment Due to Alzheimer's Disease

☐ G30.0 Early Onset Alzheimer's Disease

☐ G30.1 Late Onset Alzheimer's Disease

☐ G30.8 Other Alzheimer's Disease

☐ G30.9 Alzheimer's Disease unspecified

☐ Other: _____

REQUIRED DOCUMENTATION: Please include insurance card (front & back), all patient demographics, history & physicals, medication lists, recent lab results (CBC, CMP, TB, Hep B panel-depending on medication), signed prescription order and recent visit notes.

Confirm that these and the required lab orders have been sent to American Infusion Care and necessary parties.

PRESCRIPTION INFORMATION

Nursing: Provide nursing care per American Infusion Care - Specialty Infusions protocols, including reaction management and post-procedure observation

Pre-Medications

☐ Acetaminophen (Tylenol) ☐ 500mg ☐ 650mg ☐ 1000mgPO

☐ Cetirizine (Zyrtec) 10mgPO

☐ Loratadine (Claritin) 10mgPO

☐ Diphenhydramine (Benadryl) ☐ 25mg ☐ 50mg ☐ PO ☐ IV

☐ Methylprednisolone (Solu-Medrol) ☐ 40mg ☐ 125mg IV

☐ Other: _____ Dose: _____ Route: _____

Lab Orders

Required: ApoE ε4 Testing (if available)

Cognitive Assessment Score _____ (MMSE 20-28, CDR-GS 0.5 or 1)

MRI Within 1 Year Confirmed presence of amyloid pathology

CMS Registry Confirmation ALZH- _____ (Medicare and Medicare

Advantage only)

Patient has been provided ARIA Risk counseling

☐ Other: _____

*****Referring provider is responsible for obtaining an MRI prior to the 5th, 7th, and 14th infusions**

Legembi (lecanemab-irmb) (Select one):

☐ 10 mg/kg (_____ mg) IV every 2 weeks

☐ 10 mg/kg (_____ mg) IV every 4 weeks (after 18 months of treatment only)

☐ Other: _____

Maintenance Dose: (can only be selected once patient has completed 18 months of standard dosing at the 2 week interval per the PI)

☐ 10mg/kg (_____ mg) IV every 4 weeks

☐ Other: _____

Post Treatment Observations: The patient is required to stay for 30 minutes following the first administration.

Refills: ☐ zero ☐ 6 months ☐ 12 months ☐ _____ (Prescription valid for one year, unless otherwise indicated)

Special Instructions: _____

PROVIDER INFORMATION

Provider Full Name: _____ Provider NPI #: _____ Specialty: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____

Provider Name (Print)

Provider Signature

Date